Currently, the iNOS inhibitor L-NMMA in combination with pembrolizumab, is in clinical phase I study for the treatment of NSCLC and small cell lung cancer (SCLC), among other cancer types (NCT03236935). Here, NOS2 is linked to non-small cell lung carcinoma.